ALIM Alimera Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALIM

Price (delayed)

$3.44

Market cap

$180.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.84

Enterprise value

$232.69M

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or ...

Highlights
The EPS has soared by 68% from the previous quarter and by 68% YoY
Alimera Sciences's gross profit has soared by 51% YoY and by 18% from the previous quarter
ALIM's debt is up by 46% year-on-year
Alimera Sciences's quick ratio has decreased by 11% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.alimerasciences.com
Peers: REGN INSM ALDX TTOO

Key stats

What are the main financial stats of ALIM
Market
Shares outstanding
52.35M
Market cap
$180.1M
Enterprise value
$232.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.91
Price to sales (P/S)
1.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.88
Earnings
Revenue
$80.75M
EBIT
-$9.86M
EBITDA
-$1.12M
Free cash flow
-$14.52M
Per share
EPS
-$0.84
Free cash flow per share
-$0.57
Book value per share
$0.88
Revenue per share
$3.16
TBVPS
$2.2
Balance sheet
Total assets
$153.52M
Total liabilities
$107.35M
Debt
$64.68M
Equity
$46.17M
Working capital
$30.51M
Liquidity
Debt to equity
1.4
Current ratio
2.39
Quick ratio
2.13
Net debt/EBITDA
-47.17
Margins
EBITDA margin
-1.4%
Gross margin
86.6%
Net margin
-24.9%
Operating margin
-2.4%
Efficiency
Return on assets
-16.7%
Return on equity
-69.9%
Return on invested capital
-12.5%
Return on capital employed
-7.5%
Return on sales
-12.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALIM stock price

How has the Alimera Sciences stock price performed over time
Intraday
-3.1%
1 week
-10.65%
1 month
-14%
1 year
69.45%
YTD
-20.37%
QTD
-11.79%

Financial performance

How have Alimera Sciences's revenue and profit performed over time
Revenue
$80.75M
Gross profit
$69.92M
Operating income
-$1.93M
Net income
-$20.13M
Gross margin
86.6%
Net margin
-24.9%
ALIM's operating margin has soared by 89% YoY and by 66% QoQ
The operating income has soared by 83% year-on-year and by 59% since the previous quarter
Alimera Sciences's gross profit has soared by 51% YoY and by 18% from the previous quarter
The revenue rose by 49% year-on-year and by 18% since the previous quarter

Growth

What is Alimera Sciences's growth rate over time

Valuation

What is Alimera Sciences stock price valuation
P/E
N/A
P/B
3.91
P/S
1.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.88
The EPS has soared by 68% from the previous quarter and by 68% YoY
The equity is down by 5% since the previous quarter
The stock's P/S is 56% more than its 5-year quarterly average of 0.7 and 21% more than its last 4 quarters average of 0.9
The revenue rose by 49% year-on-year and by 18% since the previous quarter

Efficiency

How efficient is Alimera Sciences business performance
Alimera Sciences's return on assets has surged by 58% YoY and by 22% QoQ
ALIM's ROIC has soared by 55% YoY and by 37% from the previous quarter
ALIM's ROE has soared by 55% QoQ
The ROS has grown by 46% YoY and by 36% from the previous quarter

Dividends

What is ALIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALIM.

Financial health

How did Alimera Sciences financials performed over time
Alimera Sciences's total assets is 43% more than its total liabilities
ALIM's total liabilities has soared by 69% YoY
The current ratio has declined by 12% since the previous quarter
ALIM's debt is 40% greater than its equity
The debt to equity has soared by 166% YoY and by 6% from the previous quarter
ALIM's debt is up by 46% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.